Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden ADHD: study reveals how many adults are undiagnosed

NCT ID NCT04943796

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 224 adults who already had at least one psychiatric condition to see how many also had undiagnosed ADHD. Researchers measured how often ADHD was missed and tracked quality of life in those diagnosed. The goal is to highlight the need for better detection of ADHD in adults with other mental health disorders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could raise awareness about undiagnosed ADHD in adults with other mental health conditions, potentially leading to better screening practices.
What could go wrong
This is an observational study with no treatment being tested, so it cannot prove cause and effect. Results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

224 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with diagnosis of any of the following psychiatric disorder: Major depressive disorder (MDD), Anxiety disorders (AD), Bipolar disorders (BD), Substance use disorders (SUD), Border line disorder and Binge eating disorder.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: Part I: * Adult greater than or equal to (\>=)18 years of age or Canadian adult \>=19 years of age * Ability to consent, as judged by the study investigator * Diagnosis of at least one psychiatric disorder of at least 12 months duration, based on International classification of diseases (ICD)-10 codes registered in electronic health records * Consecutive assessment for ADHD (as per routine clinical practice) * Able to read and write in the first language of the respective country Part II * Inclusion in study Part I * Diagnosis of ADHD during Part I, according to routine diagnostic procedure and algorithms * Anticipated availability for being followed over 9 months Exclusion criteria: Part I: * Diagnosis of any of the following at any time prior to signing informed consent: schizoaffective disorder, intellectual disability, or other cognitive disorders * Occurrence of any of the following events within the 6 months prior to signing consent: psychotic episodes, acute intoxication, or psychotropic drug withdrawal syndrome. * Diagnosis of ADHD at any time before study inclusion * Serious and unstable medical condition (severe disease that limits survival to 1 year) * Participation in a clinical interventional trial in the 12 months prior signing consent Part II: \- Participant being followed-up for ADHD in a different site

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention-deficit/hyperactivity disorder (ADHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder psychiatric disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention-deficit/hyperactivity disorder (ADHD)

Contacts and locations

Locations

  • Asklepios Klinikum Hamburg

    Hamburg, 21075, Germany

  • Charité - Universitätsmedizin Berlin

    Berlin, 10117, Germany

  • Clínica Dr. Quintero

    Madrid, 28002, Spain

  • Cumbria Northumb, Tyne & Wear FT, Adult Psychiatry Dept

    Newcastle upon Tyne, NE3 3XT, United Kingdom

  • Hopital de Psychiatrie de Trois-Rivières, Pavillon St-Joseph

    Trois-Rivières, Quebec, G9A 5Z9, Canada

  • Hospital Vall d'Hebron

    Barcelona, 08035, Spain

  • Hs. Infanta Elena

    Madrid, 28342, Spain

  • Klinik und Poliklinik für Psychiatrie und Psychoterapie

    Bonn, 53127, Germany

  • Pacific Coast Recovery Care

    Burnaby, British Columbia, V3N3N4, Canada

  • Psykiatrisk klinik Umeå

    Umeå, 907 37, Sweden

  • Regina Mental Wellness Clinic

    Regina, Saskatchewan, S4P0W6, Canada

  • Tees Esk and Wear Valley foundation

    York, YO31 8TA, United Kingdom

  • University Hospitals of Geneva

    Geneva, 1205, Switzerland

  • Universitätsklinikum Frankfurt am Main

    Frankfurt am Main, 60596, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.